Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose Therapy with Stem Cell Support in Elderly Relapsed Aggressive NHL (FIL_RecAnz)
NCT02371161Phase 2Unknown
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Feb 2014
- Primary completion
- Dec 2018
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab, dexamethasone, cisplatin, cytarabine, etoposide and 2 more in non-Hodgkin lymphoma (NHL), sponsored by Fondazione Italiana Linfomi. Primary endpoints: Event Free Survival at 36 months and Treatment Related Mortality at 100 days. Status: unknown.
02
Drugs
rituximabdexamethasonecisplatincytarabineetoposide
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT02371161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02371161.